drugset / Trial / NCT00158548
ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan
Phase 3
Completed
650 enrolled
London School of Hygiene and Tropical Medicine
HealthNet TPO · collabMalaria Control Program, Directorate of Malaria Control, Pakistan · collabUnited Nations High Commissioner for Refugees · collabWorld Health Organization · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
Chloroquine resistant falciparum malaria in Pakistan is prevalent in every malarious area examined. Resistance to the favoured second-line treatment, sulphadoxine-pyrimethamine S/P is rising fast. To avert a repetition of the resistance catastrophe that occurred in SE Asia it is critical to preserve the effective life of SP by using it in combination with artesunate. Efficacy of ACT with artesunate in combination with chloroquine, SP or amodiaquine for treatment of malaria (falciparum or vivax) will be examined in malaria patients in Pakistan.
Timeline
- Start
- 2001-06
- Primary completion
- —
- Completion
- 2004-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Artesunate | Small molecule | — | — |
| Subject | Chloroquine | Small molecule | — | — |
| Subject | Primaquine | Small molecule | — | — |
| Subject | SP, chloroquine, amodiaquine, primaquine, artesunate | Unknown | — | — |
| Subject | amodiaquine | Other / unclassified | — | — |